New Psychedelic CPT Codes: Paving the Way for a New Age of Psychiatric Care

On June 4, the US Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee will host a meeting that could bring the US closer to a new age in the management of psychiatric illnesses, with the committee preparing to discuss an application from Lykos Therapeutics for midomafetamine (MDMA) capsules in management of post-traumatic stress disorder (PTSD).^1,2